Tumor ablation is a minimally invasive surgical procedure for the treatment of solid tumors. Unique probes are used to "burn" or "freeze" tumors without surgery. The needle probe is guided and placed into cancer using computed tomography (CT), ultrasound, or magnetic resonance imaging (MRI). Compared to open surgery, this type of therapy requires less anesthesia, causes minor trauma and discomfort, and patients stay in the hospital for shorter periods and recover faster. Ablation can decrease tumors, which can prolong life, relieve discomfort, and even cure cancer in rare situations.
Ablation is a procedure that kills a tumor in the liver without removing it. When a patient has a few small tumors and surgery is not an option, this approach can be helpful. Furthermore, patients receiving such treatment are less likely to require hospitalization, resulting in a higher likelihood of ablation system adoption among individuals. An increasing prevalence of breast cancer, colon cancer, prostate cancer, and lung cancer is expected to increase demand for ablation technologies used to treat kidney, soft tissue, liver, and bone tumors. As the leading cause of death, cancer is considered a universal health problem. As a result, the rising global prevalence of cancer is expected to provide considerable growth prospects for market players over the forecast period.
Ablation device improvements have improved accuracy, mobility, and cost-effectiveness, prompting market participants to launch and upgrade new devices on a regular basis. Some of the significant technological breakthroughs in the industry are irreversible electroporation, HIFU, cryoablation, and image-guided equipment. Larger and more complex cancers in various organs can now be treated thanks to advancements in existing technology and the advent of innovative ablation procedures. In addition, advances in intraprocedural imaging aim to improve treatment quality and reduce complications. Intraprocedural imaging advancements have improved treatment preparation and provided a precise assessment of the ablation zone during treatment.
The financial load on the healthcare system is growing as the aging population grows. As the population of the elderly grows, so will the demand for ablation devices for tumor therapy, boosting the market. Furthermore, disorders like cancer and diabetes are pervasive among the elderly, who are more prone to experience complications following chemotherapy or surgical treatment. As the body's primary systems deteriorate with age, the geriatric population is the primary target demographic for noninvasive ablation techniques. As a result, the expanding senior population is expected to drive demand for tumor ablation systems during the projected period.
Several malignant and benign tumors can be treated with minimally invasive procedures to minimize the discomfort, pain, and recovery time associated with traditional surgery. Such procedures may only involve a local anesthetic and may be a viable alternative for many people who are not surgical candidates. Faster healing, smaller incisions, less scarring and pain, better precision, and shorter hospital stays are advantages of minimally invasive surgery. Because procedures including ultrasound, radiofrequency ablation, and laser ablation are minimally invasive, the tumor ablation market is likely to grow over the forecast period due to increased demand for minimally invasive surgery.
North America is anticipated to hold the largest market share of USD 1,063 million by 2030 at a CAGR of 13.3% during the forecast period. Government support for excellent healthcare, high disposable income, reimbursement availability, and the increasing prevalence of cancer in the United States and Canada are all factors contributing to its expansion. Europe is the second contributor to the tumor ablation market and is anticipated to hold a market share of USD 1,038 million by 2030 at a CAGR of 13%. Public funding in Europe's healthcare system has boosted the market. The growing geriatric population and government cancer support have expanded the market.
The tumor ablation market in Asia-Pacific is expected to witness exponential growth. Collaborative partnerships and bilateral agreements with companies in this region create growth opportunities. Latin America and the Middle East and Africa have the lowest market. Increased geriatric population, cancer prevalence, minimally invasive diagnostics, and public-private partnerships will boost the tumor ablation business.
The key players in the global tumor ablation market are